Entities / Company
Tonix Pharmaceuticals.
commercial pharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 29
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
Gone quiet
No new reports in 90+ days-
Tonix Medicines, Inc. became a commercial subsidiary of Tonix Pharmaceuticals on July 21, 2025.Some support1 report
-
Tonix Pharmaceuticals was included in the Russell indexes on July 1, 2025.Speculative2 reports
-
Tonix Pharmaceuticals announced a collaboration with Columbia University Medical School, and Seth Lederman was identified as the CEO of the company.Speculative1 report
-
Tonix Pharmaceuticals is conducting the OASIS study at the University of North Carolina, where Sina Bavari serves as Executive Vice President of Infectious Disease Research and Development.Speculative1 report
-
The FDA approved Tonix Pharmaceuticals' drug, Tonmya, for use in treating fibromyalgia.Well supported3 reports
-
Tonix Pharmaceuticals conducted an OASIS study at the University of North Carolina.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Tonix Pharmaceuticals this week
News at the entities that move Tonix Pharmaceuticals most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Tonix Pharmaceuticals
-
Raymond James Financial Mentioned togetherRaymond James Financial reiterated an outperform rating on FinWise Bancorp.Moves Tonix Pharmaceuticals
-
MarketBeat Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Tonix Pharmaceuticals
Connections
The 7 strongest of 29, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA granted designations and final approval for Tonix's drug, Tonmya, enabling its commercial launch.
-
Seth Lederman Structural
Seth Lederman serves as the Chief Executive Officer of Tonix Pharmaceuticals.
-
University of North Carolina Structural
Tonix Pharmaceuticals utilizes the University of North Carolina for clinical trials and drug development studies.
-
Raymond James Financial Mentioned together
Raymond James Financial provides analyst coverage that influences Tonix Pharmaceuticals' stock rating and price.
-
Valneva SE Mentioned together
Both Valneva SE and Tonix Pharmaceuticals are described as small-cap healthcare companies.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and market coverage for Tonix Pharmaceuticals.
-
Frederick Shared context
Tonix Pharmaceuticals operates a research facility located in Frederick, Maryland.
History
Events by the month they beganSeptember 2026
3 events- Tonix Pharmaceuticals CEO Seth Lederman purchased company stock in an insider transaction, while analyst coverage influences stock rating.
- Tonix Pharmaceuticals and Valneva are both identified as small-cap healthcare companies.
- Market comparison of small-cap biotechs involving Tonix Pharmaceuticals and Protalix Biotherapeutics.
June 2026
6 events- Tonix Medicines, Inc. became a commercial subsidiary of Tonix Pharmaceuticals on July 21, 2025.
- Tonix Pharmaceuticals was included in the Russell indexes on July 1, 2025.
- Tonix Pharmaceuticals announced a collaboration with Columbia University Medical School, and Seth Lederman was identified as the CEO of the company.
- Tonix Pharmaceuticals is conducting the OASIS study at the University of North Carolina, where Sina Bavari serves as Executive Vice President of Infectious Disease Research and Development.
- The FDA approved Tonix Pharmaceuticals' drug, Tonmya, for use in treating fibromyalgia.
- Tonix Pharmaceuticals conducted an OASIS study at the University of North Carolina.